Filing Flows › Viridian Therapeutics (VRDN) › Recalls, complaints & regulation
Viridian Therapeutics (VRDN): clinical trials
Viridian Therapeutics (VRDN) beyond its filings: 4 active clinical trials.
Viridian Therapeutics' latest quarter
Viridian Therapeutics, Q3 2026: revenue $25.8M (-64% year over year), operating margin -401.8%, net loss $101M, operating cash flow −$92.8M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Viridian Therapeutics have?
4 active studies on ClinicalTrials.gov, 3 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.